DavidAlanBondMD

PubMed

• 15 citations
  Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
  Adam Zayac, Andrew M. Evens, Alexey V. Danilov, Stephen D. Smith, Deepa Jagadeesh
  Haematologica. 2021-07-01
• 24 citations
  Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
  Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio C. Chavez, Yago Nieto
  Blood Advances. 2021-03-23
• 32 citations
  CAR T-cell therapy for B-cell lymphoma.
  Nathan Denlinger, David Bond, Samantha Jaglowski
  Current Problems in Cancer. 2022-02-01

Abstracts/Posters

• Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
  David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
  David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
  David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Second cancer incidence in CLL patients receiving BTK inhibitors. 
  2019 ASCO Annual Meeting - 6/1/2019